Literature DB >> 18598323

Plasma nitrate/nitrite (NOx) is not a useful biomarker to predict inherent cardiopulmonary bypass inflammatory response.

Fernanda Viaro1, Caroline Floreoto Baldo, Verena Kise Capellini, Andrea Carla Celotto, Solange Bassetto, Alfredo José Rodrigues, Paulo Roberto Barbosa Evora.   

Abstract

BACKGROUND AND AIM: There were strong evidences that nitric oxide has capital importance in the progressive vasodilatation associated with varied circulatory shock forms, including systemic inflammatory response syndrome (SIRS), in patients undergoing cardiac surgeries for cardiopulmonary bypass (CPB). If CPB procedures, per se, are the inciting stimulus for inflammation, plasma nitrate/nitrite (NOx) excretion would be expected to be higher in these patients rather than in patients operated without CPB. In consequence, we hypothesized that increased levels of NOx would be predictive for vasoplegic syndrome.
METHODS: Thirty patients were assigned to three groups: Group 1--coronary artery bypass graft (CABG) roller pump CPB; Group 2--CABG centrifugal vortex pump CPB; and Group 3--heart valve surgery roller pump CPB. Sampling of venous blood for chemiluminescence plasma NOx dosage was achieved at the following time points: (1) before anesthesia induction; (2) after anesthesia induction; (3) before heparin infusion; (4) after heparin infusion; (5) CPB-30 minutes; (6) CPB-60 minutes; (7) before protamine infusion; (8) after protamine infusion; and (9) on return to the recovery area.
RESULTS: There were no intergroup differences regarding age and anesthetic regimen, and the number of arteries grafted was not different between the CABG groups. There were no NOx statistic differences, neither among the three groups of patients or among the surgery time. In addition, there was no correlation among NOx, lactate, and hemoglobin.
CONCLUSIONS: Considering the inflammatory process intrinsic to CPB, this study reinforces the idea that plasma NOx is not useful as a biomarker of inflammatory response onset, which may or may not lead to SIRS and/or vasoplegic syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18598323     DOI: 10.1111/j.1540-8191.2008.00649.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  5 in total

1.  Methylene blue does not have to be considered only as rescue therapy for distributive shock.

Authors:  Paulo Roberto Barbosa Evora
Journal:  J Med Toxicol       Date:  2013-12

2.  Inflammatory Biomarkers in Cardiac Surgery and the Suggestion of an Editors' Heart Team.

Authors:  Paulo Roberto B Evora; Bruno Pinheiro; Domingo M Braile
Journal:  Braz J Cardiovasc Surg       Date:  2018 Nov-Dec

3.  Effects of methylene blue in acute lung injury induced by oleic acid in rats.

Authors:  Ana Paula Cassiano Silveira; Daniella Alves Vento; Agnes Afrodite Sumarelli Albuquerque; Andrea Carla Celotto; Cristiane Tefé-Silva; Simone Gusmão Ramos; Tales Rubens de Nadai; Alfredo José Rodrigues; Omero Benedicto Poli-Neto; Paulo Roberto Barbosa Evora
Journal:  Ann Transl Med       Date:  2016-01

Review 4.  Twenty years of vasoplegic syndrome treatment in heart surgery. Methylene blue revised.

Authors:  Paulo Roberto Barbosa Evora; Lafaiete Alves Junior; Cesar Augusto Ferreira; Antônio Carlos Menardi; Solange Bassetto; Alfredo José Rodrigues; Adilson Scorzoni Filho; Walter Vilella de Andrade Vicente
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Jan-Mar

5.  Influence of Hypoxic and Hyperoxic Preconditioning on Endothelial Function in a Model of Myocardial Ischemia-Reperfusion Injury with Cardiopulmonary Bypass (Experimental Study).

Authors:  Irina A Mandel; Yuri K Podoksenov; Irina V Suhodolo; Darya A An; Sergey L Mikheev; Andrey Yu Podoksenov; Yulia S Svirko; Anna M Gusakova; Vladimir M Shipulin; Andrey G Yavorovskiy
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.